Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Research & Development (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Research & Development readings, the most recent being $4.1 million for Q4 2022.

  • On a quarterly basis, Research & Development rose 47.88% to $4.1 million in Q4 2022 year-over-year; TTM through Dec 2022 was $14.5 million, a 67.85% increase, with the full-year FY2025 number at $10.0 million, down 1.97% from a year prior.
  • Research & Development hit $4.1 million in Q4 2022 for Cardiol Therapeutics, up from $3.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $4.1 million in Q4 2022 to a low of $1.7 million in Q2 2021.